NASDAQ : IBRX
ImmunityBio, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 8.27 USD (Oct 30, 2026, 12:41 PM EDT) · Market cap 8.76B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 8.79B |
| Enterprise Value | 9.66B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 1.06B |
| Shares Outstanding | 1.06B |
| Shares Change (YoY) | +26.61% |
| Shares Change (QoQ) | +2.26% |
| Owned by Insiders (%) | 27.89% |
| Owned by Institutions (%) | 19.88% |
| Float | 406.69M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 52.99 |
| Forward PS | 31.56 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 58.25 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 5.72 |
| Quick Ratio | 5.35 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2.20 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -30.54% |
| Return on Invested Capital (ROIC) | -69.10% |
| Return on Capital Employed (ROCE) | -45.63% |
| Weighted Average Cost of Capital (WACC) | 4.78% |
| Revenue Per Employee | $239,931 |
| Profits Per Employee | -$1.44M |
| Employee Count | 691 |
| Asset Turnover | 0.32 |
| Inventory Turnover | 0.26 |
Taxes
| Measure | Value |
|---|
| Income Tax | -161,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.03 |
| 52-Week Price Change | +242.56% |
| 50-Day Moving Average | 8.71 |
| 200-Day Moving Average | 7.90 |
| Relative Strength Index (RSI) | 43.81 |
| Average Volume (20 Days) | 13,889,969 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 122.95M |
| Short Previous Month | 124.09M |
| Short % of Shares Out | 11.60% |
| Short % of Float | 30.23% |
| Short Ratio (days to cover) | 7.96 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 165.79M |
| Gross Profit | 164.70M |
| Operating Income | -251.80M |
| Pretax Income | -992.58M |
| Net Income | -992.36M |
| EBITDA | -235.30M |
| EBIT | -251.80M |
| Loss Per Share | -$0.99 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 357.37M |
| Total Debt | 1.23B |
| Net Cash | -871.03M |
| Net Cash Per Share | -$0.82 |
| Equity (Book Value) | -1.05B |
| Book Value Per Share | -0.99 |
| Working Capital | 362.25M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -281.14M |
| Capital Expenditures | -6.94M |
| Depreciation & Amortization | 16.50M |
| Net Borrowing | 74.96M |
| Free Cash Flow | -288.07M |
| FCF Per Share | -$0.27 |
Margins
| Measure | Value |
|---|
| Gross Margin | 99.34% |
| Operating Margin | -151.88% |
| Pretax Margin | -598.69% |
| Profit Margin | n/a |
| EBITDA Margin | -141.92% |
| EBIT Margin | -151.88% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -26.61% |
| Shareholder Yield | -26.61% |
| Earnings Yield | -11.93% |
| FCF Yield | -3.28% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $14.25 |
| Price Target Difference | 71.89% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | 124.51% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -8.87 |
| Piotroski F-Score | 3 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |